BioSpace News Archive

Triple Ring Technologies, a co-development firm that helps innovators and entrepreneurs develop breakthrough science-based technologies, is pleased to announce that the company has been awarded an SBIR Phase I grant by the Food and Drug Administration entitled An e-beam sterilization dose map simulation tool.

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced it has signed a memorandum of understanding with the National Health Service in England.

Gladstone scientists help explain how reducing the protein tau can prevent abnormal brain activity associated with Alzheimer’s disease, autism, and epilepsy

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced executive leadership changes that reflect the company’s growth and plans for advancing minimally invasive care globally.

NeuroPace, Inc., (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.

T2 Biosystems, Inc. today announced the appointment of Laura Adams to its Board of Directors, effective immediately.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing access to easy and reliable TB testing, especially in high burden countries, low-resource regions.

Prime Medicine, Inc., a company founded to deliver on the promise of Prime Editing, announced the addition of capabilities to its platform based on recent scientific research.

Evert Kroon , Ph.D., Vice President of Translation Research at ViaCyte, Inc. will participate in the International Pancreas & Islet Transplantation Association (IPITA) Virtual Congress’ session, " Islet Organoids From Pluripotent and Adult Stem Cells " on Friday, October 22, 2021 from 8:05-9:05 a.m. ET.

Seal Rock Therapeutics, Inc. today announced completion of the single ascending dose (SAD) portion of its Phase 1 clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 (ASK1) for Non-Alcoholic SteatoHepatitis (NASH) and other liver diseases such as Alcoholic Hepatitis (AH).